Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Melanoma Clinical Trial
Data on melanoma clinical trial described by researchers at Slotervaart Hospital
December 10th, 2008
Investigators publish new data in the report 'GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.' "For the treatment of melanoma DNA vaccines are a promising therapeutic approach. In our institute a plasmid encoding a melanoma-associated epitope (MART-1) and an immunostimulatory sequence (tetanus toxin fragment-c) termed pDERMATT was developed," scientists in Amsterdam, Netherlands report. "In a phase I study the plasmid will be administered intradermally using a newly developed tattoo strategy to assess the toxicity and efficacy of inducing tumor-specific T-cell immunity. To facilitate this study a Good Manufacturing Practice...
Source: Vaccine Weekly (2008-12-10)
|
